Barinthus Biotherapeutics’ Post

#NEWS: We named Geoffrey M. Lynn, MD, PhD as our Chief Scientific Officer. Dr. Lynn, also the co-inventor of SNAP-TI, brings more than 15 years of experience leading immunotherapeutic R&D from discovery through early development. Dr. Lynn will transition to his new role starting December 1, 2024.  Read the full release: https://lnkd.in/emyG-S-z #immunotherapy #celiacdisease #biotechnews #healthcare #innovation #cso #leadership #csuite

Joshua Bernstock MD, PhD

Harvard Medical School | Brigham and Women's Hospital | Boston Children's Hospital | Massachusetts Institute of Technology

3mo

Let’s go Geoff!!!!

Congrats!🎉

Like
Reply
Lindsay Iserman

Project Management and Operations Leader in Medical Education and Healthcare.

3mo

way to go Geoff!

Like
Reply
Matthew Carpenter, RTTP

Deputy Head of Licensing & Ventures - Life Sciences at Oxford University Innovation Ltd.

3mo

Congratulations Geoff!

Like
Reply

축하드려요!

Like
Reply

Congrats Geoffrey!

Darrell Irvine

Professor at the Scripps Research Institute

3mo

Congrats Geoff!

Like
Reply
Daniel M. Jacobs, Sr.

Chairman/CEO, The Federal Market Group, Ltd., CPCM, CMC; Chairman, The Subcontract Management Institute

3mo

Congrats!

Like
Reply
John Magnani

Entrepreneur, Biotech Executive, Drug Discovery

3mo

Congrats!

Like
Reply
Bill Enright

Barinthus Biotherapeutics, CEO

3mo

Congratulations Geoff! Looking forward to working with you in this new role!

See more comments

To view or add a comment, sign in

Explore topics